Mid-Morning Look: August 17, 2022

Auto PostDaily Market Report

Mid-Morning Look

Wednesday, August 17, 2022

Index

Up/Down

%

Last

 

DJ Industrials

-202.77

0.59%

33,949

S&P 500

-36.13

0.84%

4,268

Nasdaq

-198.81

1.52%

12,903

Russell 2000

-30.30

1.51%

1,990

 

 

U.S. stocks sliding initially following mixed results in retail earnings (LOW, TGT, TJX, PLCE), a report showing overall U.S. retail sales were flat in July, while the S&P 500 index failed (initially) at its 200-day moving average late yesterday around the 4,325 level – all ahead of the FOMC July meeting minutes later this afternoon. Fed speakers over the last 2-weeks have been “hawkish”, talking tough on future rate hikes as they continue to deal with high inflation. Stock markets to this point have not been listening, rising 5-straight weeks on expectations recent decelerating inflation figures (CPI, PPI, UoM expectations) will ease the pace of interest rate hikes by the Fed. Inflation a hot topic in the U.S., but over in the UK, July inflation spiked 10.1%, lifted by soaring food prices. crude futures extend morning gains after weekly EIA data showed larger-than-expected fall in U.S. crude inventories.

 

Economic Data

·     July Retail Sales unchanged, slightly below the expected +0.1% rise by economists (June downwardly revised to +0.8% from 1%; Retail Sales ex-autos +0.4% vs. est. (-0.1%; July gasoline sales (-1.8%) vs June +2.5%, cars/parts sales (-1.6%) vs June +0.5% and Retail Sales Ex-autos/gasoline +0.7% vs June +0.7%

·     June inventory/sales ratio 1.30 months’ worth vs May 1.30 months; June Business Inventories +1.4%, in-line with consensus and down from May +1.6%; June business sales +1.3% vs May +1.0%; June retail inventories ex-autos revised to +1.5%

 

 

Macro

Up/Down

Last

 

WTI Crude

1.99

88.51

Brent

0.97

93.31

Gold

-8.50

1,781.30

EUR/USD

0.00

1.0170

JPY/USD

1.06

135.27

10-Year Note

0.051

2.875%

 

 

Sector Movers Today

·     Housing & Building Products; a day after better results from HD, home improvement retailer LOW with mixed results as EPS beat but revs missed – Q2 EPS $4.67 tops consensus $4.59 but Q2 revenue of $27.48B misses consensus $28.12B; Q2 comparable sales decreased (-0.3%) vs. est. +2.3% and US comp sales rose +0.2% vs. est. +2.3% and backs FY EPS/revs; tool maker SWK downgraded to Hold from Buy at Deutsche Bank and cut tgt to $111 from $126 following better Q2 results but slashed their full year outlooks; weekly housing data showed the MBA mortgage market index falls 2.3% to 273.3 (lowest since 2000), purchase index falls 0.8% and the refinancing index falls 5.4% to 627.1, lowest since Nov 2000

·     Retailers: TGT Q2 profit badly lagged consensus and the company ratcheted up the pressure on its second half by sticking with its forecast of a dramatic rebound – Q2 adj EPS $0.39 misses the $0.72 estimate; Q2 sales rose 3.5% to $26.04B, in-line with consensus estimates; Q2 comparable sales grew 2.6% vs. est. 2.8% driven by an increase in traffic, while avg. transaction was flat; PLCE shares slide after weaker Q2 results (EPS and sales miss) on weaker margins and guided FY net sales about $1.73B, missing the $1.77B estimate; TJX lowered its guidance for annual earnings and comparable sales after posting a Q2 sales shortfall that it attributed to historic inflation; LVLU posted 2Q revenue and adjusted EBITDA results in line with its July 28 preannouncement and maintained FY guidance revised on that date; WEBR downgraded to Sell from Neutral, price target $2.75 at Citigroup saying there are too many concerns to remain on the sidelines

·     Semiconductors; ADI ported earnings and revenue for its fiscal third quarter above Wall Street consensus saying that economic uncertainty was beginning to impact bookings; for NVDA Bank America noted another guide-down unwelcome but drive necessary reset as reports earnings on 24-Aug, with consensus now aligned with recent negative preannouncement, but current FQ3 (Oct) Street consensus could have downside risk as it might not reflect the full-quarter of inventory correction in gaming/crypto products that started in late FQ2.

 

Stock GAINERS

·     A +6%; posted revenue of $1.72B (+13.2% core) with EPS of $1.34 above consensus of $1.20; raised FY22 core growth from +8-9% to +10.3-11.8% and EPS to $5.06-5.08 from $4.86-4.93

·     AAPL +0.6%; upgrade to Outperform from Neutral at Credit Suisse, and received a price target boost to $220 from $200 at Wedbush

·     HIL +61%; after saying it has agreed to be bought by privately held construction manager Global Infrastructure Solutions Inc. for $173 million.

·     LOW +2%; mixed results as EPS beat but revs missed – Q2 EPS $4.67 tops consensus $4.59 but Q2 revenue of $27.48B misses consensus $28.12B; Q2 comparable sales decreased (-0.3%) vs. est. +2.3% and US comp sales rose +0.2% vs. est. +2.3% and backs FY EPS/revs

·     PGR +2%; outperforms in financials after July results

·     SJM +1%; upgraded to Buy at Bank America and up tgt to 4155 ahead of earnings next week as think there could be upside to sales/EPS ests

 

Stock LAGGARDS

·     BPMC -21%; said a Phase 2 clinical trial evaluating Ayvakit in patients with non-advanced systemic mastocytosis met the primary and secondary endpoints…but SVB Leerink said is concerned about the change in the symptom score in the Phase 2 study, compared with the Phase 1 trial.

·     DNUT -11%; posted Q2 earnings that missed Wall Street expectations, as economic pressures cut into the company’s top and bottom lines and cuts its FY revs view to $1.49B-$1.52B vs prior forecast of $1.53B-$1.56B on lower earnings as well

·     JKHY -8%; sees 2023 EPS of $5.05-5.09, missing the Wall Street estimate of $5.30 and guides revs $2,080B-$2,08b compared with the consensus of $2.08b; lower guidance follows a top on the top and bottom line

·     LVLU -11%; posted 2Q revenue and adjusted EBITDA results in line with its July 28 preannouncement and maintained FY guidance

·     OPCH -6%; 11M share Spot Secondary priced at $33.25

·     SNY -5%; after stopping clinical development of its once-promising breast-cancer treatment amcenestrant after an independent monitoring committee said that the drug didn’t meet requirements to continue its study

·     TDOC -5%; downgraded to Neutral from Buy at Guggenheim with $25 tgt saying its revenue growth and EBITDA will remain pressured by its exposure to the consumer segment

·     TGT -4%; Q2 adj EPS $0.39 misses the $0.72 estimate; Q2 sales rose 3.5% to $26.04B, in-line with consensus estimates; Q2 comparable sales grew 2.6% vs. est. 2.8%

_________________________________________________________________

Market commentary provided by Hammerstone Markets, Inc, a firm separate from and not affiliated with Regal Securities. Regal Securities has not participated in the creation of the content, and does not explicitly or implicitly endorse the content.

Live Trading

Open an Account

Paper Trading

Register